Omeros (NASDAQ:OMER) Director Arnold Hanish Sells 10,000 Shares

Key Points

• Director Arnold Hanish sold 10,000 Omeros shares at an average price of $18.95, generating $189,500. His remaining ownership fell to 5,000 shares, a 66.67% decrease.
• Omeros shares traded at $18.58, near the 52-week high of $19.65, with a market capitalization of approximately $1.35 billion. The stock has risen well above its 50-day and 200-day moving averages.
• The company exceeded quarterly expectations, reporting $0.02 EPS versus the consensus estimate of a $0.27 loss and revenue of $28.53 million versus $12.69 million expected. Analysts maintain a “Moderate Buy” consensus with a $38 target price.

Omeros Corporation (NASDAQ:OMER - Get Free Report) Director Arnold Hanish sold 10,000 shares of the firm's stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Omeros Stock Performance

NASDAQ:OMER traded down $0.67 during mid-day trading on Friday, hitting $18.58. The company had a trading volume of 1,143,548 shares, compared to its average volume of 1,711,871. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $19.65. The firm has a market cap of $1.35 billion, a P/E ratio of 14.52 and a beta of 2.54. The business's fifty day moving average is $12.48 and its two-hundred day moving average is $11.98.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. Equities analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently made changes to their positions in OMER. International Assets Investment Management LLC increased its stake in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 800 shares during the period. Farther Finance Advisors LLC grew its holdings in shares of Omeros by 16.5% during the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 1,004 shares in the last quarter. State of Wyoming acquired a new position in Omeros in the fourth quarter valued at about $25,000. AQR Capital Management LLC lifted its position in Omeros by 7.2% during the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 1,532 shares during the period. Finally, ProShare Advisors LLC grew its stake in Omeros by 12.1% during the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company's stock worth $261,000 after buying an additional 1,637 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. HC Wainwright reiterated a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Finally, Zacks Research lowered shares of Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Omeros presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source